when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

1,499 stories

Aug 13, 26Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionbiospace

Aug 13, 26Chutes & Ladders—Former Legend CEO lands at K2fiercebiotech

Aug 13, 26Zealand sells milestone, royalty rights to rare blood cancer asset for up to $100Mbiospace

Aug 13, 26Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestendpoints

Aug 13, 26STAT+: Neurocrine Biosciences and the delicate balance of benefit and riskstat

Aug 13, 26PDS halts work on phase 3 cancer therapy to focus on colorectal contenderfiercebiotech

Aug 13, 26STAT+: As young people increasingly get cancer, new fertility options are changing their futuresstat

Aug 13, 26Opinion: How to disrupt the health misinformation business modelstat

Aug 13, 26STAT+: What patients actually think about ‘minimally invasive’ brain implantsstat

Aug 13, 26Behind the bell: Gearing up to go publicbiospace

Aug 13, 26Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalfiercebiotech

Aug 13, 26Zealand sells its rights to Takeda’s blood cancer drug for $100M ahead of FDA approval decisionfiercebiotech

Aug 13, 26Recon: FDA grants Concerta generic withdrawal hearing; Ivonescimab wins first-line NSCLC nod in Chinaraps

Aug 12, 26Talks on launch of clinical trial of Ebola vaccine in DRC advance, WHO saysstat

Aug 12, 26Vaping and cannabis hit record highs among young adults in 2025: Surveystat

Aug 12, 26Pfizer’s former chemistry whiz debuts Khartis Therapeutics with $95M for thyroid eye disease pillfiercebiotech

Aug 12, 26STAT+: Cancer patients face longer wait times to begin treatment, according to new studystat

Aug 12, 26AI clinical monitoring agent can deliver up to 82 times the ROI in oncology: reportfiercebiotech

Aug 12, 26Boulevard starts up with $65M to pursue targeted autoimmune drugsbiopharma dive

Aug 12, 26Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlightbiospace

Aug 12, 26Opinion: Climate change is making people with chronic illness even sickerstat

Aug 12, 26With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentbiospace

Aug 11, 26CytoDyn’s leronlimab reaffirms HIV potential after combo treatment eradicates virus in infant macaquesfiercebiotech

Aug 11, 26Ex-Legend CEO takes helm at biotech startup scouring the globe for drugsbiopharma dive

Aug 11, 26How we know that splitting up the MMR vaccine could be dangerousstat

Aug 11, 26FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issuesbiospace

Aug 11, 26STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and morestat

Aug 11, 26Ex-Legend chief Ying Huang becomes CEO of K2, eyes $250M Series Aendpoints

Aug 11, 26Silence causes uproar in rare blood cancer space as data sets high bar for competitorsbiospace

Aug 11, 26Vaderis gets $152M to run Phase 3 of rare bleeding disorder treatmentendpoints

← prevpage 23 of 50next →